Hansa Biopharma AB is a Pharmaceuticals company based in Sweden. With an ESG score of 28.1, the company is considered to have a medium risk assessment. Specializing in immunomodulatory treatments, Hansa Biopharma AB focuses on enabling transplantations and treating rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. Their leading product candidate, imlifidase, is an antibody-cleaving enzyme designed to facilitate kidney transplants in sensitized patients. Operating in Sweden, other European countries, and the U.S., the company generates its revenue primarily from product sales.